• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Minimal Residual Disease-Adapted Therapy in Multiple Myeloma: Current Evidence and Opinions

by | Apr 28, 2024 | Publications

Curr Oncol Rep. 2024 Apr 27. doi: 10.1007/s11912-024-01537-2. Online ahead of print. ABSTRACT PURPOSE OF REVIEW: Multiple myeloma (MM) is a biologically heterogeneous malignancy with relatively uniform treatment paradigms. This review aims to assess the growing role...

Comprehensive evaluation of genetic and acquired thrombophilia markers for an individualized prediction of clinical thrombosis in patients with lymphoma and multiple myeloma

by | Apr 28, 2024 | Publications

J Thromb Thrombolysis. 2024 Apr 27. doi: 10.1007/s11239-024-02977-0. Online ahead of print. ABSTRACT Patients diagnosed with lymphoma or multiple myeloma are at elevated risk of venous thromboembolism (VTE). Optimum risk stratification and effective thromboprophylaxis...

Another quadruplet therapy for multiple myeloma: the beginning of the end for autologous haematopoietic stem-cell transplantation?

by | Apr 28, 2024 | Publications

Lancet Haematol. 2024 Apr 24:S2352-3026(24)00097-8. doi: 10.1016/S2352-3026(24)00097-8. Online ahead of print. NO ABSTRACT PMID:38677301 | DOI:10.1016/S2352-3026(24)00097-8

Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial

by | Apr 28, 2024 | Publications

Lancet Haematol. 2024 Apr 24:S2352-3026(24)00070-X. doi: 10.1016/S2352-3026(24)00070-X. Online ahead of print. ABSTRACT BACKGROUND: Isatuximab is a CD38 monoclonal antibody approved for relapsed or refractory multiple myeloma. We aimed to evaluate the addition of...

Biological Age is No Barrier for Adult Patients Undergoing CAR T for Non-Hodgkin’s Lymphoma or Multiple Myeloma

by | Apr 28, 2024 | Publications

Transplant Cell Ther. 2024 May;30(5):462-464. doi: 10.1016/j.jtct.2024.04.002. NO ABSTRACT PMID:38677789 | DOI:10.1016/j.jtct.2024.04.002

Diagnostic value of LGE and T1 mapping in multiple myeloma patients’heart

by | Apr 28, 2024 | Publications

BMC Cardiovasc Disord. 2024 Apr 27;24(1):230. doi: 10.1186/s12872-024-03895-y. ABSTRACT BACKGROUND: Unidentified heart failure occurs in patients with multiple myeloma when their heart was involved. CMR with late gadolinium enhancement (LGE) and T1 mapping can...
« Older Entries
Next Entries »

Recent Content

  • Future Perspectives in Multiple Myeloma
  • Patients and Caregivers Aim to Raise Funds for Myeloma Research
  • GPRC5D Bispecific antibody talquetamab-induced dizziness-ataxia syndrome, clinical presentation and management- a case series
  • Symptomatic progression-free survival as an emerging patient-centered endpoint in multiple myeloma: a secondary analysis of MagnetsiMM-3 trial data
  • Blood Test Could Replace Bone Marrow Biopsies in Multiple Myeloma
  • Value of serum-free light chain measurements in response and progression assessment in multiple myeloma with monoclonal protein measurable by electrophoresis
  • Simultaneous whole-body multi-parametric 2-[18F]FDG-PET/MRI in smoldering multiple myeloma assessment: diagnostic and prognostic impact
  • SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors
  • Multiple Myeloma: A Modern Look at an Ancient Disease and 2025’s Therapeutic Breakthroughs
  • Can Cilta-Cel Redefine Outcomes in Multiple Myeloma?
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT